Reference:
Routy, J.-P., Boulassel, M.-R., Yassine-Diab, B., Nicolette, C., Healey, D., Jain, R., Landry, C., Yegorov, O., Tcherepanov, I., Monesmith, T., Finke, L., & Sékaly, R.-P. (2010). Immunologic activity and safety of autologous HIV RNA–electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clinical Immunology, 134(2), 140. https://doi.org/10.1016/j.clim.2009.09.009
Summary:
This pilot study assessed the immunogenicity and safety of AGS-004, an autologous dendritic cell-based immunotherapy for HIV-1 infected individuals on antiretroviral therapy (ART). Ten patients received injections of AGS-004, produced from their monocyte-derived dendritic cells electroporated with HIV RNA antigens and CD40L. Results indicated full or partial HIV-specific immune responses in 7 out of 9 evaluable subjects, predominantly targeting CD8+ T cells. Adverse effects were mild, including flu-like symptoms and injection site reactions, with no significant changes in viral load or T cell counts. The findings support further clinical investigations into AGS-004 as a viable immunotherapeutic option for enhancing anti-HIV immune responses.